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Introduction {#sec001}
============

Nontyphoidal *Salmonellae* (NTS) are a major cause of food borne infections throughout the developed and developing world \[[@pntd.0005118.ref001]\]. Although infection most often results in self-limited acute gastroenteritis, NTS have been identified as a major cause of invasive bacterial infections in infants and young children in sub-Saharan Africa and HIV-infected individuals of all ages \[[@pntd.0005118.ref002],[@pntd.0005118.ref003]\]. Invasive NTS (iNTS) disease is recognized as a problem in developed countries in young infants, the elderly and immunocompromised \[[@pntd.0005118.ref004]\]. iNTS disease is caused mainly by *Salmonella enterica* serovars Typhimurium and Enteritidis \[[@pntd.0005118.ref005],[@pntd.0005118.ref006]\].

NTS gastroenteritis is generally understood to be acquired from animal reservoirs, unlike *Salmonella* Typhi and *Salmonella* Paratyphi, where the only recognized reservoir is man. Transmission of gastroenteritis-causing NTS to humans can occur by many routes, including consumption of animal food products, especially eggs, poultry, undercooked meat, produce contaminated with animal waste, contact with animals or their environment, and contaminated water \[[@pntd.0005118.ref007],[@pntd.0005118.ref008]\].The African strains responsible for iNTS disease are characterized by genome degradation and appear to be increasingly adapted to an invasive lifestyle \[[@pntd.0005118.ref009]\]. The relative role of animal reservoirs and human to human transmission of strains causing iNTS disease is unclear \[[@pntd.0005118.ref010],[@pntd.0005118.ref011]\]. iNTS disease is diagnosed definitively by blood or bone marrow culture, usually with low sensitivity \[[@pntd.0005118.ref012]\]. It is also impossible to diagnose using clinical symptoms alone due to the lack of pathognomonic features \[[@pntd.0005118.ref005],[@pntd.0005118.ref006]\]. There is currently no commercially-available rapid diagnostic test for iNTS disease.

Bacteraemia is an important cause of severe and often fatal disease globally, especially in developing countries (where it substantially contributes to childhood deaths) \[[@pntd.0005118.ref002],[@pntd.0005118.ref013]\]. Invasive forms of *Salmonella* disease include enteric fevers (typhoid and paratyphoid fevers) and NTS bacteraemia and are important causes of morbidity and mortality in Asia and Africa \[[@pntd.0005118.ref003],[@pntd.0005118.ref014],[@pntd.0005118.ref015]\]. In a review article of bacteraemia in Africa from 2010, NTS was found to be responsible for 29.1% of all bloodstream infections \[[@pntd.0005118.ref016]\]. Nevertheless, the data on NTS bacteraemia in Africa are limited with no current aggregate data, so it has been difficult to estimate the burden of NTS bacteraemia in Africa. Such information is vital for planning and implementing cost-effective solutions \[[@pntd.0005118.ref017]\] to tackle iNTS disease, especially in Africa with its fragile health-care systems. Infectious diseases are a major obstacle to human development in the African region with people suffering from an extensive range of potentially preventable and treatable conditions including invasive *Salmonella* disease. Adequate evidence on the burden of *Salmonella* infections would enable health policy makers to make informed decisions on the need for vaccines against *Salmonella* infections in their country and region.

The aim of the present study is to address this knowledge gap by conducting a review of the available reports on NTS bacteraemia in Africa and to describe the epidemiology of the disease; in order to inform effective prevention and control strategies, including vaccination. Specifically, the study describes all the geographical locations in Africa that have reported iNTS disease cases, and determines incidence and proportion of bacteraemia caused by NTS (by whole population and patient groups), together with risk factors and CFR of NTS bacteraemia.

Methods {#sec002}
=======

Search strategy {#sec003}
---------------

We searched PubMed (including MEDLINE) and Embase. The search string used was: *(algeria OR angola OR benin OR botswana OR "burkina faso" OR burundi OR cameroon OR "cape verde" OR "central african republic" OR chad OR comoros OR "ivory coast" OR "cote d ivoire" OR congo OR djibouti OR egypt OR "equatorial guinea" OR eritrea OR ethiopia OR gabon OR gambia OR ghana OR guinea OR "guinea bissau" OR kenya OR lesotho OR liberia OR libya OR madagascar OR malawi OR mali OR mauritania OR mauritius OR morocco OR mozambique OR namibia OR niger OR nigeria OR rhodesia OR rwanda OR "sao tome" OR senegal OR seychelles OR "sierra leone" OR somalia OR "south africa" OR sudan OR swaziland OR tanzania OR togo OR tunisia OR uganda OR "western sahara" OR zambia OR zimbabwe OR Africa) AND (fever OR fevers OR bacteremia OR bacteremias OR bacteremic OR bacteraemia OR bacteraemias OR bacteraemic OR septicemia OR septicemias OR septicemic OR septicaemia OR septicaemias OR septicaemic OR salmonella OR salmonellas OR salmonellae OR "blood stream infection" OR "blood stream infections" OR "blood stream pathogen" OR "blood stream pathogens" OR febrile) AND (infant\* OR child\* OR adolescent\* OR adult\* OR patient OR patients OR human OR travel\* OR communit\* OR village\* OR participant\* OR volunteer\* OR subject\* OR incidence OR hospital OR man)*.

We used the United Nations list of 54 African Sovereign states as the basis for searching, modified by including Rhodesia (name had changed during the search period) and both the English and French names for Ivory Coast. Initial tests showed that "Congo" found all references to the Democratic Republic of the Congo as well as Republic of the Congo. Similarly, "Sudan" found both Sudan and South Sudan. Although it is not recognized by the United Nations as a sovereign state, we also included "Western Sahara" in case there were reports from this area.

PubMed and Embase have, an English translation for all paper titles regardless of language, English key words (i.e. MESH terms in PubMed) and usually an English Abstract. These were the only fields searched in the initial searching for papers of any language and assumes that the English terms used in the search would be sufficient to identify papers in any language for the first pass.

Initial searches failed to find any papers prior to 1966, search results were limited to publications from 1^st^ Jan 1966 up to 31^st^ December, 2014. We imported the full texts/abstracts of the search result into Quosa Information Manager software (Quosa) \[[@pntd.0005118.ref018]\] and a full text search was done through Quosa for articles containing the term "Salmonell\*".

To ensure a comprehensive search of the literature, especially for reports within the last five years, we did an independent search on Embase database using a similar search string and strategy as above (with limit publication dates from 2009 to 2014). Additional reports that were not retrieved from the PubMed search were obtained and reviewed for inclusion.

Selection criteria {#sec004}
------------------

The full text of the search results of online articles/abstracts were reviewed independently by the study authors (IVU, CAM and AS) with the aim of including articles that used blood culture to isolate NTS from humans in Africa Inconsistences between the papers included by the different authors were resolved by consensus. The full text version either obtained on line or ordered, when only the abstract was available on line, of potentially relevant articles was retrieved and reviewed critically using predetermined inclusion and exclusion criteria for the study. This was done for articles, regardless of the published language. The reference sections of retrieved full text articles were reviewed critically in search of further potential articles for inclusion.

### Inclusion criteria {#sec005}

Studies were included if they:

1.  Reported NTS isolated by blood culture

2.  Were conducted in and recruited subjects from Africa;

### Exclusion criteria {#sec006}

Studies were excluded if they:

1.  Described NTS disease isolated by stool culture only without blood culture result

2.  Did not specify serovar of *Salmonella enterica* isolated (for example, *Salmonella* Typhi or one of the serotypes causing NTS)

### Validity assessment {#sec007}

Study validity was established by use of the selection criteria described above, thereby excluding studies that were thought likely to have results that are either inaccurate, not representative of the reported population or could otherwise not be compared with studies included in the analysis. Studies were not excluded on the basis of potential variability of microbiological techniques and identification of culture isolates.

Review of the selected literature {#sec008}
---------------------------------

### Data extraction and collection process {#sec009}

Relevant descriptive and quantitative variables were extracted from each of the selected article. A standardised template was used for the data extraction in the form of a Microsoft Excel 2013 workbook with each column of the database corresponding to one of the fields in the template. Double data extraction and entry was performed to ensure accuracy. The variables extracted from each article included name of journal, title of article, publication date, study location (including city, country and region in Africa), study period, patient age, and primary eligibility criteria). Quantitative data collected included number of potential study participants, subjects enrolled, participants who had blood cultured, significant pathogens isolated, NTS pathogens isolated; iNTS disease incidence (if stated), CFR of iNTS disease, and proportion of study participants with risk factors such as infection with malaria or human immunodeficiency virus (HIV) (if known). Where publications separately included data derived from more than one cohort of subjects (e.g. different age groups), each unique study was included as a separate entry in the table. The fields used are listed in [S1 Table](#pntd.0005118.s003){ref-type="supplementary-material"}.

### Data analysis {#sec010}

Data were cleaned and a descriptive analysis performed with the aid of Microsoft Excel 2013. All reported measures of disease frequency were directly drawn from the literature.

Duplicate reports of iNTS disease cases were sorted and removed from the final analysis or, where this was not possible, clearly identified as potentially overlapping (See supplementary [S2 Table](#pntd.0005118.s004){ref-type="supplementary-material"} for listing of relevant reports). The sorting was done by grouping all reports according to country and then comparing variables including study dates, name and location of the study site, age group of subjects reported, number of blood cultures taken and number of NTS isolated across the studies from each country for potential overlaps.

Incidence data were extracted directly from studies where this was stated and summarized according to sub-group classification, subjects, location, study date, groups at risk and possible risk factors. Incidence was derived in a few studies by dividing the total number of NTS isolated by the population at risk per unit time (year) and stated as cases per 100,000 person year of observation or per 100,000 population per year.

Proportion of NTS as the cause of community acquired blood stream infection was calculated using the formula: *number of* NTS *bacteraemic cases divided by total number of significant/pathogenic bacteraemia in the relevant studies*. Relevant studies included prospective and retrospective hospital-based blood culture series for subjects presenting with fever with no known focus of infection or groups of subjects not selected for possible associated risk factors as anaemia, HIV, malaria and malnutrition.

CFR data were extracted directly from the studies where given. CFR was calculated using the formula: *death amongst* NTS *bacteraemia cases divided by total* iNTS *disease cases multiplied by 100*. The CFR data were then summarized according to subjects, location, study period and possible risk factors.

Summary data for risk factors associated with iNTS disease in Africa were extracted directly from the studies where available. Statistically-significant measures of association, such as odds ratio (OR), risk ratio (RR) and prevalence proportion were extracted from the studies.

Results {#sec011}
=======

Search results {#sec012}
--------------

The online database search performed on PubMed (completed in February, 2015), using the search string and limiting the results from 1^st^ January 1966 to 31^st^ December 2014, yielded 16,638 articles. These were retrieved in Quosa and a full text search for the term '*Salmonella*' using Quosa yielded a subset of 1,979 articles. The abstract and full text (where available) of the 1,979 articles obtained were reviewed manually for relevance based on our criteria. 177 articles were finally selected from PubMed and entered into the database ([Fig 1](#pntd.0005118.g001){ref-type="fig"}). We found more publications using our search string with all the countries in Africa included by name, than with "Africa" alone, and by not restricting publications by using 'human' as a search term. The articles retrieved in Quosa were published in 16 languages of which French (216 articles) was the most common following English.

![Strategy for selection of eligible articles.\
Adapted from the PRISMA group 2009 flow diagram \[[@pntd.0005118.ref203]\].](pntd.0005118.g001){#pntd.0005118.g001}

A similar search strategy was used on the Embase database with the initial search results limited to articles in Embase only, humans and the period 2009 to 2014, yielding 8034 articles (in February, 2015). 736 articles were obtained following a full text search for the term '*Salmonella*' in Quosa. Thereafter, the full texts of these articles were reviewed manually and 13 additional unique articles not obtained from the initial PubMed search were added to the database (including 9 abstract-only articles).

One hundred and ninety articles \[[@pntd.0005118.ref002],[@pntd.0005118.ref003],[@pntd.0005118.ref010],[@pntd.0005118.ref011],[@pntd.0005118.ref013],[@pntd.0005118.ref019]--[@pntd.0005118.ref202]\] were obtained following the literature search and used for the descriptive analysis in our review ([Fig 1](#pntd.0005118.g001){ref-type="fig"}). Following a further review of these articles, 14 ([S2 Table](#pntd.0005118.s004){ref-type="supplementary-material"}) reporting cases or cohorts of iNTS disease already reported in another published article were excluded from the quantitative analysis, leaving 176 articles including 12 studies with possibly overlapping data ([S2 Table](#pntd.0005118.s004){ref-type="supplementary-material"}). These 176 studies included 223 distinct subject cohorts.

The reports varied in their methodology. Three of the 176 articles were reports from ill subjects in a longitudinal, community-based surveillance. 159/176 (90%) of all articles retrieved are reports of isolates obtained from studies conducted on ill subjects presenting to a health facility setting (hospital or clinic). In fourteen of the reports, we could not determine the original basis for selecting the subjects (E.g., retrospective analysis of microbiology laboratory samples, follow up analyses of bacteraemia in patients previously selected for another study). However, most of these 14 were probably from ill subjects presenting to a health facility.

Only 9 (5%) were designed to derive an estimate of the population-based incidence of iNTS disease in Africa; 76 (43.2%) were prospective hospital-based studies with patients recruited during the course of the study; 22 (12.5%) were retrospective studies with analysis of existing hospital or laboratory records; and the remaining 69 (39.2%) are case reports, series, conference abstracts or outbreak reports.

A total of 18,931 isolates of NTS were reported in this review. These included 9,084 isolates of *Salmonella enterica* serovar Typhimurium (*S*. Typhimurium) (48%), 2,801 isolates of *S*. Enteritidis (15%), 1,215 other serovars (6%) and 5,831 'not further typed' (31%).The category 'other serovars' includes, but is not limited to, less common serovars: 197 Infantis, 155 Wien, 88 Dublin, 71 Newport, 71 Bovis-morbificans, 92 Isangi, 24 Heidelberg, 8 Havana and 9 Ordonez \[[@pntd.0005118.ref011],[@pntd.0005118.ref040],[@pntd.0005118.ref049],[@pntd.0005118.ref065],[@pntd.0005118.ref068],[@pntd.0005118.ref071],[@pntd.0005118.ref091],[@pntd.0005118.ref104],[@pntd.0005118.ref108]\]. *Salmonella* Typhimurium is therefore the most common serovar reported for iNTS disease in Africa and approximately three times (48% vs 15%) more common than *S*. Enteritidis.

Geographical location of sites reporting iNTS disease in Africa {#sec013}
---------------------------------------------------------------

iNTS disease was reported in 33 countries across the five geographical regions of Africa based on the United Nations classification ([Fig 2](#pntd.0005118.g002){ref-type="fig"}). The majority, 53% (94/176) of the reports were from the Eastern Africa region (including 28 reports from Kenya, 24 from Malawi, 16 from Tanzania and 10 from Uganda); 26% (46/176) from the Western Africa region (including 9 reports from Cote d'Ivoire, 9 from Nigeria and 8 from Ghana); 10% (17/176) from Central Africa (including 11 reports from Democratic Republic of Congo, 3 from Gabon and 2 from Central African Republic); 7% (12/176) from Northern Africa (including 5 reports from Tunisia and 2 each from Morocco and Algeria); and 4% (7/176)from Southern Africa (South Africa) ([S3 Table](#pntd.0005118.s005){ref-type="supplementary-material"}).

![Map of Africa showing number of publications from countries reporting NTS blood culture isolates.\
Regions are indicated using coloured boundaries based on United Nations classification](pntd.0005118.g002){#pntd.0005118.g002}

Details of the study population or study site setting could be extracted from only 113 of the 176 reports obtained. 50.4% (57/113) of the reports were from urban sites, 38.9% (44/113) from rural sites and 10.6% (12/113) from both urban and rural sites ([S4 Table](#pntd.0005118.s006){ref-type="supplementary-material"}).

59.2% (11,211/18,931) of the total NTS isolates were reported from the Eastern Africa region (6,057 isolates from Malawi, 2,976 isolates from Kenya and 767 isolates from Uganda). 14.9% (2,819/18,931) and 13.5% (2,558/18,931) of isolates were from Southern (2,819 isolates from South Africa) and Western Africa (788 isolates from Mali, 371 from Cote d'Ivoire and 345 from Ghana) respectively. 6.2% (1,180/18,931) and 6.1% (1,163/18,931) of isolates were from Central (1,003 isolates from Democratic Republic of Congo, 138 from Gabon and 34 from Central African Republic) and Northern Africa (1,023 isolates from Algeria, 100 from Tunisia and 36 from Morocco) respectively ([Fig 3](#pntd.0005118.g003){ref-type="fig"}).

![Regional distribution of iNTS disease cases reported from Africa (1966 to 2014).\
Graph shows total numbers of NTS isolates reported and numbers of publications in which cases were reported.](pntd.0005118.g003){#pntd.0005118.g003}

Reports based on year of publication {#sec014}
------------------------------------

The earliest report of iNTS disease was published in 1966 \[[@pntd.0005118.ref069]\] and the numbers of reports of iNTS disease increased with time to a peak of 18 reports in 2011 ([Fig 4](#pntd.0005118.g004){ref-type="fig"}). 55.7% (98/176) of the reports obtained were published within the last decade (2005 to 2014), with 35.8% (63/176) were published in the last 5 years (2010 to 2014).

![Published reports of iNTS disease in Africa by year of publication](pntd.0005118.g004){#pntd.0005118.g004}

A similar trend can also be observed in the total number of NTS blood culture isolates with time. 67.5% (12770/18931) of the total isolates were reported within the last ten years (2005 to 2014), while 22.3% (4218/18931) were reported in the last 5 years (2010 to 2014).

Incidence of iNTS disease in Africa {#sec015}
-----------------------------------

Fourteen reports on the incidence of iNTS disease in Africa were obtained from eight countries--the Gambia, Ghana, Kenya, Malawi, Mozambique, South Africa, Tanzania & Uganda, spanning three regions, Eastern (ten studies), Southern (one) and Western (three) ([Table 1](#pntd.0005118.t001){ref-type="table"}). The incidence data were obtained using different methods of estimation and were from different population groups including specific age groups, HIV-infected patients and subjects with sickle cell disease. Overall, the estimated incidence of iNTS disease ranged from 1.4 per 100,000 population/year (in South African individuals of all ages in 2003 to 2004) to 2,520 per 100,000 population per year in children \< 5 years of age from Ashanti, rural Ghana, in 2007 to 2009.

10.1371/journal.pntd.0005118.t001

###### Published reports of incidence of iNTS disease in Africa (1966 to 2014)

![](pntd.0005118.t001){#pntd.0005118.t001g}

  Region                          Ref no.                      Study                    Study place & time                                          iNTS Incidence/100,000 person years (C.I)   iNTS incidence in Sub group                                                                                                                                                Subjects                                                Study type                                Age                       Total Blood Cultures   Total bacter-aemia   Population                               All iNTS   Comments
  ------------------------------- ---------------------------- ------------------------ ----------------------------------------------------------- ------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ----------------------------------------- ------------------------- ---------------------- -------------------- ---------------------------------------- ---------- -------------------------------------------------------------------------------------------------------------------
  Eastern                         \[[@pntd.0005118.ref002]\]   Berkley et al, 2005      Kilifi, rural Kenya; August 1998 to July 2002                                                           \<1 yr old: 170; \<2 yr old: 175; \<5 yr old: 88                                                                                                                           All acute medical admissions                            Hospital based, Prospective consecutive   \<13 years                16,570                 1,094                189,148 (15% births in study hospital)   166        Estimated minimal incidence
                                  \[[@pntd.0005118.ref122]\]   Mandomando et al, 2009   Manhiça, rural Mozambique; May 2001 to April 2006           **S. Typhimurium: 78.6 (65.4--94.3);**      \<1 year: 240.4 (169.1--341.8); 1--4 years: 176.2 (141.5--219.3);≥ 5 years: 4.5 (1.7--12.1)                                                                                Febrile admissions                                      Prospective consecutive                   \<15 years                19,896                 1,550                140,000                                  263        Minimal incidence
                                                               Mandomando et al, 2009   Manhiça, rural Mozambique; May 2001 to April 2006           **S. Enteritidis: 28.9 (21.2--38.8)**       \<1 year: 108.6 (64.3--183.3); 1--4 years: 59.5 (40.8--86.7); ≥ 5 years: 1.1 (0.16--8.1)                                                                                   Febrile admissions                                      Prospective consecutive                   \<15 years                19,896                 1,550                140,000                                  101        Minimal incidence
                                  \[[@pntd.0005118.ref129]\]   Mtove et al, 2011        Muheza, rural Tanzania; June 2006 to May 2010               **82 (No Confidence interval)**             2006--7: 82; 2007--8: 14; 2008--9: 17; 2009--10: 7                                                                                                                         Severely ill admissions                                 Hospital based prospective                2 months to \< 15 years   6,836                  684                  123,613 (average)                        232        Minimal incidence, pooled analysis
                                  \[[@pntd.0005118.ref131]\]   Muyanja et al, 2011      Entebbe, semi-urban Uganda; January 2000 to December 2008                                               Pre-[\*](#t001fn001){ref-type="table-fn"}ART1: 730 (290--1,830); Pre-ART2: 2,930 (1,910--4490); Interim: 1100 (600--2,020); ART1: 710 (370--1,360); ART2: 800 (100--540)   HIV-1 infected outpatients                              Prospective cohort                        ≥15 years                                        246                  2,540                                    66         Periods (year) include: Pre-ART1 (2000--1); Pre-ART2 (2001--3); Interim (2003--5); ART1 (2005--7); ART2 (2007--8)
                                  \[[@pntd.0005118.ref160]\]   Sigauque et al, 2009     Manhiça, rural Mozambique; May 2001 to April 2006           **120 (103--139)**                          \<1 year: 388 (294--512); 1-\<5 years: 262 (219--314); \>5 years: 6 (3--15)                                                                                                Admissions with fever or malnutrition                   Hospital based                            \<15 years                19,896                 1,550                140,000 (43% children \<15 years)        397        Minimal incidence
                                  \[[@pntd.0005118.ref164]\]   Tabu et al, 2012         Asembo, rural Kenya; October 2006 to September 2009         **580 (229--934)**                          0--4 years: 2,085 (1,181--2990); 5--9 years: 389 (106--672); 10--17 years: 24 (0--62); 18--49 years: 367 (186--550); \>50 years: 232 (112--351)                            Febrile or Acute respiratory illness                    Prospective cohort                        ≤50 years                 3,578                  155                  25,000                                   60         Extrapolated for patient samples not cultured or who visited another clinic (sampling)
                                                               Tabu et al, 2012         Kibera, urban Kenya; March 2007 to February 2009            **57 (0--122)**                             0--4 years: 260 (102--419); 5--9 years: 37 (1--73); 10--17 years: 0 (NA); 18--49 years: 11.2 (0--31); \>50 years: 0 (NA)                                                   Febrile or Acute respiratory illness                    Prospective cohort                        ≤50 years                 2,138                  230                  30,000                                   7          age stratified years (1--4; 5--9; 10--17; 18--49; \>50) S. Typhi more common
                                  \[[@pntd.0005118.ref174]\]   Williams et al, 2009     Kilifi, rural Kenya; August 1998 to March 2008              **1,580 (1,080--2,230)**                    0--11 months: 360 (70--1050); 12--23 months: 1,080 (220--3,150);2--13 years: 1,430 (760--2,440)                                                                            All admissions with sickle cell anaemia                 Case-control, retrospective               \<14 years                                       108                  100,000                                  19         Incidence in patients with Sickle cell anaemia
                                  \[[@pntd.0005118.ref123]\]   Mayanja et al, 2010      Southwest Uganda; January 1996 to December 2007             **855 (617--1223)**                         13--24 yrs: 713 (328--1850);                                                                                                                                               Fever without detectable malaria                        Population-based HIV clinical cohort      All ages                  703                    159                  20,000                                   42         37.7% HIV prevalence in cohort
  25--34 yrs: 883 (533--15720);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  35--44 yrs: 1395 (789--2708);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  45+ yrs: 375 (142--1332).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  HIV negative: 37 (5--266);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  HIV, no ART:2070(1480--2980);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  HIV pos, ART:739 (237--3533)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                  \[[@pntd.0005118.ref076]\]   Feikin et al, 2013       Asembo, Kenya; March 2007 to February 2010                  **1200 (570--1800)**                                                                                                                                                                                                   Patients with severe acute respiratory illness          Hospital-based, prospective               \< 5 years old            747                    24                                                            14         
                                  \[[@pntd.0005118.ref083]\]   Gordon et al, 2008       Blantyre, Malawi; Jan 1998 to Dec 2004                      **164**                                                                                                                                                                                                                Febrile, clinical sepsis                                Hospital based, prospective               All ages                  62,878                 10,628               502053                                   4955       Minimal incidence--derived from the data
  Southern                        \[[@pntd.0005118.ref011]\]   Feasey et al, 2010       South Africa; January 2003 to December 2004                 **1.4**                                                                                                                                                                                                                All                                                     Active laboratory surveillance data       All ages                  ND                     ND                   46,000,000                               1318       Population based; Derived from data
  Western                         \[[@pntd.0005118.ref067]\]   Enwere et al, 2006       Basse & Bansang, rural Gambia; August 2000 to April 2004    **Group A- 262 (190--354)**                 2--5 months: 227 (74--530); 6--11 months: 407 (237--652); 12--17 months: 238 (114--438); 18--23 months: 233 (100--458); 24--29 months: 126 (26--369)                       Vaccine trial participants suspected with bacteraemia   Part of vaccine trial                     2 to 29 months            7369                   295                  ND                                       92         Prospective cohort from the population
                                                               Enwere et al, 2006       Basse & Bansang, rural Gambia; August 2000 to April 2004    **Group B- 300 (222--397)**                 2--5 mo: 408 (187--775); 6--11 mo: 360 (201--594); 12--17 mo: 334 (183--561); 18--23 mo: 293 (140--539); 24--29 mo: 42 (1--236)                                            Vaccine trial participants                              Part of vaccine trial                     2 to 29 months            7369                   295                  ND                                       93         Prospective cohort from the population
                                  \[[@pntd.0005118.ref184]\]   Marks et al, 2012        Agogo, rural Ghana; Jan 2010 to Oct 2011                                                                \<5 years: \>600                                                                                                                                                           Febrile in & outpatients                                2 year Surveillance data                  All ages                  5134                   389                  38882                                    ND         Abstract only, survey used to adjust incidence calculation
                                  \[[@pntd.0005118.ref137]\]   Nielsen et al, 2012      Ashanti, rural Ghana; September 2007 to July 2009           **2520 (2110--2940)**                       Nil                                                                                                                                                                        Admissions                                              Prospective consecutive                   \< 5 years                1196                   238                  149500 (15% aged \<5 years)              129        Incidence adjusted based on health-seeking behaviour

\*ART anti-retroviral therapy

The incidence rates were much higher in Eastern and Western Africa compared to Southern Africa. Across the studies, the estimated incidence rates were higher amongst HIV-infected subjects \[[@pntd.0005118.ref123],[@pntd.0005118.ref131]\], subjects with sickle cell disease\[[@pntd.0005118.ref174]\], young children\[[@pntd.0005118.ref122],[@pntd.0005118.ref160],[@pntd.0005118.ref164]\] and in a rural setting compared to an urban setting \[[@pntd.0005118.ref164]\].

Three studies estimated iNTS disease in the community. These studies were conducted on subjects from all age groups, and without bias for risk factors such as HIV infection, malaria and anaemia. Estimates obtained were 1.4, 164 and \>600 per 100,000 population per year from South Africa, Malawi and Ghana respectively \[[@pntd.0005118.ref011],[@pntd.0005118.ref083],[@pntd.0005118.ref184]\].

Proportion of NTS as a cause of community acquired blood stream infection in Africa {#sec016}
-----------------------------------------------------------------------------------

Fifty six studies, describing a total of 114,634 blood cultures ([S5 Table](#pntd.0005118.s007){ref-type="supplementary-material"}) from four regions were eligible for analysis: hospital-based studies from Africa investigating the organisms causing bacteraemia in the community and not in any specific risk group. Eligible studies were from four of the five regions (all except the Northern region) and sixteen countries in Africa. NTS proportions varied between and within regions. Regional averages ranged from 8% in Southern Africa to 38% in Central Africa with an overall average of 25%. In Eastern Africa, with an average of 27%, the range was 9% in Ethiopia to 39% in Malawi while in Western Africa, with an average of 18%, the range was 8% in Nigeria to 34% in Burkina Faso.

Across countries, NTS was a cause of about 8% (lowest value) of community acquired bacteraemia in both Nigeria and South Africa to a peak value of 45% in one study from Central African Republic involving 131 blood cultures ([Fig 5](#pntd.0005118.g005){ref-type="fig"}). Variations in NTS proportion within country were found in Malawi, Kenya, Tanzania and Uganda. This suggests that it might be difficult to directly extrapolate the burden of iNTS disease within a country as well as from one country to another.

![Proportion of Community acquired blood stream infections caused by NTS in African countries (1966 to 2014)](pntd.0005118.g005){#pntd.0005118.g005}

An analysis of the relative frequencies of different organisms causing community acquired bacteraemia in Africa was performed and it showed that NTS, *Staphylococcus aureus* and *Streptococcus pneumoniae* are most prevalent organisms isolated over time in Africa ([Fig 6](#pntd.0005118.g006){ref-type="fig"}). Since the selection of articles included in this review excluded blood culture series without NTS, there is an element of bias favouring NTS compared to other organisms. However, the review of Reddy et al \[[@pntd.0005118.ref016]\] also indicated the importance of iNTS as a cause of community acquired blood stream infection amongst adults and children in Africa \[[@pntd.0005118.ref016]\].

![Pathogens reported from community acquired bacteraemia cases in Africa (1966 to 2014)](pntd.0005118.g006){#pntd.0005118.g006}

Risk factors associated with iNTS disease in Africa {#sec017}
---------------------------------------------------

The risk factors known to be associated with iNTS disease in Africa include HIV infection, malnutrition, malaria, young age, anaemia and rural setting ([Table 2](#pntd.0005118.t002){ref-type="table"}).

10.1371/journal.pntd.0005118.t002

###### Risk factors associated with iNTS disease in Africa (1966 to 2014)

![](pntd.0005118.t002){#pntd.0005118.t002g}

             [Risk factor]{.ul}                                [Ref no]{.ul}                [Author, Year]{.ul}             [Measure of association reported (Confidence interval)]{.ul}   [Comments]{.ul}
  ---------- ------------------------------------------------- ---------------------------- ------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------------
  [1]{.ul}   [**HIV infection**]{.ul}                                                                                                                                                      
                                                               \[[@pntd.0005118.ref031]\]   [Archibald et al, 2000]{.ul}    [OR: 4.4 (0.6--93)\*]{.ul}                                     [P value not significant]{.ul}
                                                               \[[@pntd.0005118.ref002]\]   [Berkley et al, 2005]{.ul}      [OR: 3.21 (1.95--5.28)]{.ul}                                   [OR adjusted for age, HIV infection and malnutrition]{.ul}
                                                               \[[@pntd.0005118.ref055]\]   [Bronzan et al, 2007]{.ul}      [OR: 11.6 (2.1--63.7)]{.ul}                                    [Children with severe malarial anaemia]{.ul}
                                                                                                                            [Adjusted OR: 22.1 (3.3--146)]{.ul}                            
                                                               \[[@pntd.0005118.ref156]\]   [Seydi et al, 2005]{.ul}        [Prevalence: 81% vs 36%]{.ul}                                  [P = 0.00001, iNTS in patients with vs without HIV]{.ul}
                                                               \[[@pntd.0005118.ref081]\]   [Gilks et al, 1990]{.ul}        [OR: 48.2 (13--176)]{.ul}                                      [S. Typhimurium only]{.ul}
                                                               \[[@pntd.0005118.ref051]\]   [Blomberg et al, 2007]{.ul}     [Prevalence: 25% vs 8.4%]{.ul}                                 [P = 0.022; iNTS in HIV infected vs uninfected patients]{.ul}
                                                               \[[@pntd.0005118.ref151]\]   [Peters et al, 2004]{.ul}       [OR: 5.3 (1.2--2.2)]{.ul}                                      
  [2]{.ul}   [**Malnutrition**]{.ul}                                                                                                                                                       
                                                               \[[@pntd.0005118.ref002]\]   [Berkley et al, 2005]{.ul}      [OR: 1.68 (1.15--2.44)]{.ul}                                   [OR adjusted for age, HIV infection and malnutrition]{.ul}
             [Severe (WAZ\<-3)]{.ul}                           \[[@pntd.0005118.ref122]\]   [Mandomando et al, 2009]{.ul}   [OR: 1.44 (1.08--1.91)]{.ul}                                   [P = 0.004; iNTS vs Other bacteraemia; Multivariate analysis]{.ul}
             [wasting]{.ul}                                    \[[@pntd.0005118.ref137]\]   [Nielsen et al, 2012]{.ul}      [OR: 1.9 (1.2--3.4)]{.ul}                                      
                                                               \[[@pntd.0005118.ref160]\]   [Sigauque et al, 2009]{.ul}     [OR: 2.42 (1.92--3.04)]{.ul}                                   [Unadjusted analysis]{.ul}
             [Severe acute]{.ul}                               \[[@pntd.0005118.ref192]\]   [Biggs et al, 2014]{.ul}        [OR: 2.01 (1.15--3.52)]{.ul}                                   [P = 0.014; Multivariate analysis]{.ul}
  [3]{.ul}   [**Malaria**]{.ul}                                                                                                                                                            
             [*P*. *falciparum*]{.ul}                          \[[@pntd.0005118.ref122]\]   [Mandomando et al, 2009]{.ul}   [OR: 1.61 (0.91--1.47)]{.ul}                                   [P = 0.8; iNTS vs Other bacteraemia; Univariate analysis]{.ul}
             [*P*. *falciparum* in children \>6 mo old]{.ul}   \[[@pntd.0005118.ref086]\]   [Graham et al, 2000]{.ul}       [RR: 1.5 (1.2--2.2)]{.ul}                                      [P\<0.01; compared to other pathogens combined]{.ul}
             [Recent malaria]{.ul}                             \[[@pntd.0005118.ref192]\]   [Biggs et al, 2014]{.ul}        [OR: 4.13 (2.66--6.44)]{.ul}                                   [P\<0.001; Multivariate analysis]{.ul}
  [4]{.ul}   [**Age**]{.ul}                                                                                                                                                                
             [12--23 months vs \>5 years old]{.ul}             \[[@pntd.0005118.ref002]\]   [Berkley et al, 2005]{.ul}      [Prevalence: 23% vs 7%]{.ul}                                   [P value (\<0.001)]{.ul}
             [≥2 vs \<2 years]{.ul}                            \[[@pntd.0005118.ref055]\]   [Bronzan et al, 2007]{.ul}      [OR: 4.3 (0.8--22.9)]{.ul}                                     [Children with severe malarial anaemia]{.ul}
                                                                                                                            [Adjusted OR: 9.6 (1.4--64.8)]{.ul}                            
             [2--11 months]{.ul}                               \[[@pntd.0005118.ref122]\]   [Mandomando et al, 2009]{.ul}   [OR: 2.07 (1.07--4.01)]{.ul}                                   [P = \<0.001; iNTS vs Other bacteraemia; Multivariate analysis]{.ul}
             [1--4 yrs]{.ul}                                   \[[@pntd.0005118.ref122]\]   [Mandomando et al, 2009]{.ul}   [OR: 3.90 (2.06--7.40)]{.ul}                                   [P = \<0.001; iNTS vs Other bacteraemia; Multivariate analysis]{.ul}
  [5]{.ul}   [**Anaemia**]{.ul}                                                                                                                                                            
             [Moderate]{.ul}                                   \[[@pntd.0005118.ref122]\]   [Mandomando et al, 2009]{.ul}   [OR: 1.86 (1.34--2.58)]{.ul}                                   [P = \<0.001; iNTS vs Other bacteraemia; Multivariate analysis]{.ul}
             [Severe]{.ul}                                     \[[@pntd.0005118.ref122]\]   [Mandomando et al, 2009]{.ul}   [OR: 3.48 (2.03--5.95)]{.ul}                                   [P = \<0.001; iNTS vs Other bacteraemia; Multivariate analysis]{.ul}
             [Severe]{.ul}                                     \[[@pntd.0005118.ref086]\]   [Graham et al, 2000]{.ul}       [Risk Ratio: 7.2 (3.4--15.3)]{.ul}                             [P\<0.0001; compared to other pathogens combined]{.ul}
             [Sickle cell]{.ul}                                \[[@pntd.0005118.ref174]\]   [Williams et al, 2009]{.ul}     [OR: 35.6 (16.4--76.8)]{.ul}                                   [Age adjusted (\<14years)]{.ul}
             [Anaemia (Hb\<7)]{.ul}                            \[[@pntd.0005118.ref151]\]   [Peters et al, 2004]{.ul}       [OR: 2.2 (1.1--4.5)]{.ul}                                      
             [Severe]{.ul}                                     \[[@pntd.0005118.ref192]\]   [Biggs et al, 2014]{.ul}        [OR: 2.19 (1.48--3.23)]{.ul}                                   [P\<0.001; Multivariate analysis]{.ul}
  [6]{.ul}   [**Setting**]{.ul}                                                                                                                                                            
             [Rural ward residence]{.ul}                       \[[@pntd.0005118.ref192]\]   [Biggs et al, 2014]{.ul}        [OR: 2.23 (1.25--3.96)]{.ul}                                   [P = 0.006; Univariate analysis]{.ul}

\*OR Odds Ratio

Seven studies from Africa showed a positive association between HIV and iNTS disease in Africa. The estimated odds ratio (OR) from the studies for HIV-infected individuals developing iNTS disease compared with HIV-uninfected individuals ranged from 3.2 to 48.2. The strong association between HIV infection and iNTS disease in Africa was described in 1990 when Gilks et al reported an OR of 48.2 (confidence interval 13--176) in Nairobi, Kenya \[[@pntd.0005118.ref081]\].

Malnutrition had a positive association with iNTS disease in five studies ([Table 2](#pntd.0005118.t002){ref-type="table"}), with the earliest study published in 2005. The OR for iNTS disease occurring in children with malnutrition compared with children without malnutrition ranged from 1.44 to 2.42. *Plasmodium falciparum* malaria had a positive association with iNTS disease in three African studies ([Table 2](#pntd.0005118.t002){ref-type="table"}) since the year 2000. The estimated OR for iNTS disease in individuals with *Plasmodium falciparum* malaria compared with those without *Plasmodium falciparum* malaria ranged from 1.5 to 4.1. In one study, recent history of malaria was positively associated with iNTS disease\[[@pntd.0005118.ref192]\]. Young age was associated with iNTS disease in three studies ([Table 2](#pntd.0005118.t002){ref-type="table"}). The OR for iNTS disease in young individual compared to older individuals ranged from 2.07 to 4.30. In one study of children 1--4 years of age, iNTS disease was reported to be more associated with age when compared to other organisms causing bacteraemia\[[@pntd.0005118.ref122]\].

Anaemia (especially moderate and severe anaemia), was shown by five studies to be associated with iNTS disease in Africa with reported OR ranging from 1.86 to 35.6. Rural settlement compared to urban was found by one study to be associated with iNTS disease \[[@pntd.0005118.ref192]\]. The OR of iNTS disease occurring in a rural settlement compared to an urban settlement was 2.23

Case Fatality Rate (CFR) of iNTS disease in Africa {#sec018}
--------------------------------------------------

We were able to extract CFR data for iNTS disease in Africa from twenty four studies ([Table 3](#pntd.0005118.t003){ref-type="table"}), describing a total of 548 deaths among 2656 cases. The overall CFR was 20.6%. and ranged from 0% in individuals greater than or equal to 5 years old in Kenya \[[@pntd.0005118.ref075]\] to 72.7% in another Kenyan study involving only HIV-infected patients \[[@pntd.0005118.ref081]\]. The average CFR, derived from 8 studies \[[@pntd.0005118.ref003],[@pntd.0005118.ref067],[@pntd.0005118.ref089],[@pntd.0005118.ref093],[@pntd.0005118.ref152],[@pntd.0005118.ref160],[@pntd.0005118.ref172],[@pntd.0005118.ref188]\] conducted among low risk populations (not HIV-infected, anaemic, malnourished, or having malaria), and with \>90 iNTS cases isolated, is 19% (276 fatalities from 1427 cases).

10.1371/journal.pntd.0005118.t003

###### CFR of iNTS disease from studies in Africa (1966 to 2014)

![](pntd.0005118.t003){#pntd.0005118.t003g}

  Author                        Ref no.                      Location; Study dates                                          CFR %      Setting                   Subjects                                 Study entry criteria                             \# iNTS cases   \# Deaths   Comments
  ----------------------------- ---------------------------- -------------------------------------------------------------- ---------- ------------------------- ---------------------------------------- ------------------------------------------------ --------------- ----------- ------------------------------------------------------------
  Bachou et al 2006             \[[@pntd.0005118.ref041]\]   Kampala, Uganda; Sep 2003 to Dec 2004                          **23.3**   rural, hospital           Inpatients \< 5 years old                Severe malnutrition                              30              7           HIV-infected subjects
  Bassat et al 2009             \[[@pntd.0005118.ref045]\]   Southern Mozambique, Mozambique; June 2003 to May 2007         **25.0**   rural, hospital           Inpatients ≤ 5 years old                 severe malaria                                   8               2           
  Berkozwit et al 1984          \[[@pntd.0005118.ref050]\]   Soweto, South Africa; January to Dec 1982                      **19.6**   urban, hospital           Inpatients \< 11 years old               All admissions                                   56              11          
  Blomberg et al 2007           \[[@pntd.0005118.ref051]\]   Dar es Salam, Tanzania; August 2001 to August 2002             **34.4**   Hospital                  Inpatients ≤ 7 years old                 clinical septicaemia                             32              11          21.6% malaria prevalence amongst participants
  Bouallegue-Godet et al 2005   \[[@pntd.0005118.ref052]\]   Sousse, Tunisia; July 2002                                     **66.7**   urban, hospital           inpatients, neonates                     ND                                               3               2           Neonates
  Brent et al 2006              \[[@pntd.0005118.ref003]\]   Kilifi, Kenya; August 1998 to July 2002                        **21.1**   rural, hospital           Inpatients \< 13 years old               *Salmonella* blood culture positive              166             35          
  Dube et al 1983               \[[@pntd.0005118.ref065]\]   Lusaka, Zambia; March to August 1980                           **20.0**   hospital                  Inpatients ≤ 2 years old                 Clinical infection                               10              2           Mostly neonates
  Enwere et al, 2006            \[[@pntd.0005118.ref067]\]   Basse & Bassang, Gambia; August 2000 to April 2004             **4.3**    rural, hospital           vaccine trial subjects, 2 to 29 months   Fever                                            92              4           Death within 28 day period
  Feikin et al 2012             \[[@pntd.0005118.ref075]\]   Asembo, Kenya; March 2007 to February 2010                     **0.0**    rural, hospital           in & outpatients ≥ 5 years old           respiratory illness                              41              0           37.9% HIV prevalence
  Gilks et al 1990              \[[@pntd.0005118.ref081]\]   Nairobi, Kenya; Nov 1988 to May 1989                           **72.7**   urban, hospital           All ages                                 Inpatients                                       11              8           10 were HIV-infected with bacteraemia on admission
  Gordon et al 2002             \[[@pntd.0005118.ref082]\]   Blantyre, Malawi;                                              **47.0**   rural & urban, hospital   Inpatients ≥ 18 years old                Not specified                                    100             47          99% HIV prevalence
  Gordon et al 2001             \[[@pntd.0005118.ref084]\]   Blantyre, Malawi; Dec 1997 to Nov 1998                         **32.9**   urban, hospital           Inpatients ≥14 years old                 Fever                                            164             54          92% HIV prevalence amongst 25 NTS cases
  Graham et al 2000             \[[@pntd.0005118.ref086]\]   Blantyre, Malawi; February 1996 to April 1998                  **24.1**   hospital                  Inpatients ≤ 14 years old                Bacteraemia                                      241             58          HIV infected subjects, 31% malaria parasitaemia prevalence
  Grant et al 1998              \[[@pntd.0005118.ref088]\]   Abidjan, Cote d\'Ivoire; Dec 1995 to March 1996                **50.0**   urban, hospital           Inpatients ≥ 18 years old                respiratory illness                              14              7           HIV infected subjects, CFR includes 3 E. Coli cases
  Green et al 1993              \[[@pntd.0005118.ref089]\]   Western Zaire, D.R.C; January 1982 to Dec. 1986                **22.7**   rural, hospital           in & outpatients ≤ 5 years old           Clinical *Salmonella*                            172             39          
  Hadfield TL et al 1985        \[[@pntd.0005118.ref093]\]   Zorzor, Liberia; October 1980 to August 1982                   **27.8**   hospital                  Inpatients ≤ 16 years old                S. Enteritidis blood culture positive            97              27          
  Mandomando et al 2009         \[[@pntd.0005118.ref122]\]   Manhiça, Mozambique; May 2001 to April 2006                    **12.2**   rural, hospital           Inpatients \< 10 years old               Fever                                            344             42          NTS associated with severe malnutrition, anaemia and age
  Phoba et al 2014              \[[@pntd.0005118.ref152]\]   Equateur, Democratic Republic of Congo; Nov 2011 to May 2012   **12.0**   hospital                                                                                                            83              10          69.7% has *P*. *falciparum* infection
  Pithie et al 1993             \[[@pntd.0005118.ref154]\]   Harare, Zimbabwe;                                              **40.7**   hospital                  All ages                                 Bacteraemia                                      27              11          50% HIV prevalence
  Sigauque et al 2009           \[[@pntd.0005118.ref160]\]   Manhiça, Mozambique; May 2001 to April 2006                    **12.2**   rural, hospital           Inpatients \< 10 years old               All admissions                                   344             42          
  Sow S.O. 2011                 \[[@pntd.0005118.ref188]\]   Bamako, Mali; July 2002 to June 2010                           **20.0**   hospital                  Inpatients ≤ 10 years old                Fever                                            434             87          
  Tabu et al 2012               \[[@pntd.0005118.ref164]\]   Asembo, Kenya; October 2006 to September 2009                  **11.7**   rural, hospital           ≤ 50 years old                           Fever, respiratory illness, medical admissions   60              7           
  Vaagland et al 2004           \[[@pntd.0005118.ref165]\]   Northern Tanzania, Tanzania; July to August 2000               **60.0**   rural, hospital           Inpatients ≤ 6 years old                 Clinical septicaemia                             5               3           
  Walsh et al, 2000             \[[@pntd.0005118.ref172]\]   Blantyre, Malawi; Sept. 1996 to August 1997                    **26.2**   rural & urban, hospital   Inpatients \< 15 years old               Fever                                            122             32          median age for iNTS cases---15.5 months
                                                             **Total**                                                                                                                                                                                     **2656**        **548**     

Discussion {#sec019}
==========

Our review seeks to comprehensively document reports of iNTS disease in Africa: the number and location of the reported cases, and where available, the age of the subjects, risk factors, case fatality rates and incidence. As a result, we have included many more studies (199) than a recent review by Ao et al \[[@pntd.0005118.ref204]\] that specifically only included reports of incidence. In their database, in addition to reports from other countries they list 10 reports from 6 African countries. All 10 reports from the Ao et al study are included in the larger set of 14 reports describing incidence from 8 African countries we include in [Table 1](#pntd.0005118.t001){ref-type="table"}. Not surprisingly we find a similarly high incidence of iNTS disease in sub-Saharan Africa. Ao et al estimated the overall incidence of iNTS disease in Africa at 227 cases \[range 152--341\] per 100,000 population with 1.9 \[range 1.3--2.9\] million cases annually \[[@pntd.0005118.ref204]\]. We sought to provide a comprehensive review of the published reports of NTS bacteraemia in the peer reviewed literature and found a substantial number of reports with the earliest in 1966, interestingly about the same time as genetic studies suggest the evolution of the highly African-specific highly invasive NTS genotypes \[[@pntd.0005118.ref205],[@pntd.0005118.ref206]\].

There are limits on the comprehensiveness of our study. In particular, many of the early and non-English reports in the initial screening stage were only available to us on line as abstracts, and in some cases, just the title with MESH headings and some of these may have contained details e.g. the use of blood cultures to determine *Salmonella* bacteraemia in the text but not in the abstract that resulted in these articles not being ordered and reviewed in full. Despite these limitations, this survey highlights important findings.

As shown in [Fig 2](#pntd.0005118.g002){ref-type="fig"}, no reports were found in some countries in West Africa and in South West Africa. In view of the reported cases from neighbouring countries it seems unlikely that iNTS disease does not occur in these counties, but this highlights that gaps in the published literature almost certainly exist, e.g. due to lack of infrastructure in these countries to undertake the blood culturing required to obtain a definitive diagnosis, or the lack of researchers interested in publishing reports. Some of these gaps in the database may be addressed by examining health service records, but this is beyond the scope of the article.

As shown in [Table 1](#pntd.0005118.t001){ref-type="table"} in the papers we surveyed, the estimated incidence of iNTS disease ranged from 1.4 cases per 100,000 population per year over all age groups in South Africa to a yearly cumulative incidence of 2,520 per 100,000 among \<5 years old children in Ghana. However, we caution against trying to over-interpret these incidence data or the range observed--a striking observation is the lack of consistency in the age groups reported, the inclusion criteria that may or may not select for populations with specific risk factors (e.g. HIV, sickle cell anaemia) and in the way in which the population denominator is determined for these largely facility-based studies.

On the basis of the whole database of reported bacteraemia, we confirm the earlier findings that NTS accounts for a large proportion of the bacteria responsible for community acquired blood stream infections and is a substantial cause of morbidity and mortality with the serovars Typhimurium and Enteritidis responsible for 91% of NTS bacteraemia in Africa in the 69% of cases where the serotype was determined.

A major knowledge gap exists in the incidence of iNTS disease in Africa owing to the paucity of reports from population-based surveillance of *Salmonella* in Africa. This is due to poor surveillance systems for infectious diseases in most parts of Africa. The majority of the studies on iNTS disease in Africa are hospital-based which can only provide an estimate of the minimal incidence of disease in the community, because not all febrile cases report to hospital. Denominators necessary for the detailed estimation of iNTS disease incidence in the reported publications are generally not available. This also makes it difficult to estimate the true population at risk of disease. Population-based incidence studies are best suited to estimate the incidence of an infectious disease in Africa. This can be done by either adjusting the data obtained from hospital-based study with data obtained from simultaneous health-seeking surveys carried out in the same community (for example, as has been carried out by the Typhoid Surveillance in Africa Program (TSAP) and Severe Typhoid in Africa programme \[[@pntd.0005118.ref207]\] or designing a study with a method that will allow for identification of all the cases of the disease within the target community.

Epidemiological data on iNTS disease were available from publications in peer-reviewed journals from 33 of the 54 countries in Africa ([Fig 2](#pntd.0005118.g002){ref-type="fig"}). Unavailable data from the remaining 21 African countries might be due to a lack of studies in these countries, or a true low burden of iNTS disease. These 21 countries are not involved in TSAP. It would therefore be valuable to conduct a thorough search of grey literature in the affected countries including reviewing existing databases of blood cultures carried out in major hospitals in various locations across the affected countries in the last five to ten years. Such an analysis would facilitate a better understanding of the relative importance of NTS as a cause of community acquired blood stream infection in Africa. New prospective hospital-based blood culture studies in these countries would be even more useful.

The average case fatality rate of community acquired severe infections is 20.6% but with a wide range from 0 to 72%. Therefore, the development of an effective vaccine against NTS for Africa would be an important intervention to help reduce the burden of disease and deaths due to NTS. The exact mechanisms of transmission of iNTS disease are currently unclear and there are no rapid diagnostic tests available for its detection. The development of such diagnostics would greatly facilitate the study and management of iNTS disease in Africa.
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